CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MiddleBrook Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MiddleBrook Pharmaceuticals, Inc.
20425 Seneca Meadows Parkway
Phone: (301) 944-6600p:301 944-6600 Germantown, MD  20876  United States Ticker: MBRKQMBRKQ
This company's Plan of Liquidation went into effect on 1/3/2011
On 10/01/2014, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of MiddleBrook Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.
Business Summary
MiddleBrook Pharmaceuticals, Inc. is a pharmaceutical company focused on commercializing anti-infective drug products that fulfill unmet medical needs. The Company has developed a delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. The Company’s PULSYS product, MOXATAG (amoxicillin extended-release) Tablets, 775 mg, is used for the treatment of pharyngitis/tonsillitis secondary to Streptococcus pyogenes, commonly known as strep throat, for adults and pediatric patients age 12 and older, and there is no AB-rated equivalent to MOXATAG. The Company has engaged Broadpoint Gleacher Securities Group, Inc. (Broadpoint) to assist it in identifying and evaluating strategic options, including a sale of the Company. In April 2010, the Company filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201012/31/2009YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Acting President, Chief Executive Officer, Chief Financial Officer, Executive Vice President David P.Becker 43 3/15/2010 9/4/2008
Senior Vice President, General Counsel, Secretary BradCole 42 9/1/2008 9/1/2008
Senior Vice President - Sales Operations and Administration Timothy L.Miller 53 9/5/2008 9/5/2008
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Advancis Pharmaceutical Corp
Advancis Pharmaceutical Corporation
MBRKQ

General Information
Number of Employees: 22 (As of 3/16/2010)
Outstanding Shares: 86,511,898 (As of 5/5/2010)
Shareholders: 104
Stock Exchange: OTC
Federal Tax Id: 522208264
Fax Number: (301) 944-6700


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023